Trials / Completed
CompletedNCT05902494
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
A Retrospective Chart Review of Real-world Treatment Outcomes in Patients With Locally Advanced Unresectable or Metastatic Urothelial Cancer Based on HER2 Expression
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 389 (actual)
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer. During this study, the medical and health records of participants will be reviewed to learn more about their health. Participants will have urothelial cancer that has grown in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
Conditions
Timeline
- Start date
- 2023-06-29
- Primary completion
- 2025-06-18
- Completion
- 2025-06-18
- First posted
- 2023-06-15
- Last updated
- 2025-07-20
Locations
23 sites across 4 countries: United States, Austria, France, Germany
Source: ClinicalTrials.gov record NCT05902494. Inclusion in this directory is not an endorsement.